Volume Spike Investor

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is surging on news that it signed three partnerships for Peramivir for influenza outside the U.S.   These partners will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities and for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.  BioCryst’s new partners are Moksha Pharmaceuticals for Brazil and Mexico;  NT Pharma for China; and Neopharm Group for Israel.  At 8:17 AM EST we have seen over 475,000 shares trade hands versus average volume of 2.1 million shares.  We have also seen a 16% gain to $12.49.  Be advised that the 52-week high is $13.47. -JON OGG